Biomarkers Accurately Inform Treatment Decisions in Localized Prostate Cancer.
Publication
, Journal Article
Moul, JW
Published in: Eur Urol Focus
May 2022
Biomarkers are now ubiquitous in prostate cancer care. In addition to longstanding use of prostate-specific antigen, we now have secondary serum-, urine-, and tissue-based markers that help in optimizing patient care and patient compliance with therapeutic recommendations. The ship has sailed: these markers are useful and are here to stay.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Eur Urol Focus
DOI
EISSN
2405-4569
Publication Date
May 2022
Volume
8
Issue
3
Start / End Page
641 / 642
Location
Netherlands
Related Subject Headings
- Prostatic Neoplasms
- Prostate
- Male
- Humans
- Biomarkers, Tumor
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Moul, J. W. (2022). Biomarkers Accurately Inform Treatment Decisions in Localized Prostate Cancer. Eur Urol Focus, 8(3), 641–642. https://doi.org/10.1016/j.euf.2022.05.001
Moul, Judd W. “Biomarkers Accurately Inform Treatment Decisions in Localized Prostate Cancer.” Eur Urol Focus 8, no. 3 (May 2022): 641–42. https://doi.org/10.1016/j.euf.2022.05.001.
Moul JW. Biomarkers Accurately Inform Treatment Decisions in Localized Prostate Cancer. Eur Urol Focus. 2022 May;8(3):641–2.
Moul, Judd W. “Biomarkers Accurately Inform Treatment Decisions in Localized Prostate Cancer.” Eur Urol Focus, vol. 8, no. 3, May 2022, pp. 641–42. Pubmed, doi:10.1016/j.euf.2022.05.001.
Moul JW. Biomarkers Accurately Inform Treatment Decisions in Localized Prostate Cancer. Eur Urol Focus. 2022 May;8(3):641–642.
Published In
Eur Urol Focus
DOI
EISSN
2405-4569
Publication Date
May 2022
Volume
8
Issue
3
Start / End Page
641 / 642
Location
Netherlands
Related Subject Headings
- Prostatic Neoplasms
- Prostate
- Male
- Humans
- Biomarkers, Tumor
- 3202 Clinical sciences
- 1103 Clinical Sciences